Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Total Revenue	$ 31,122	$ 29,529
Operating expenses:
Cost of testing revenue		8,513
Research and development	4,407	3,435
Selling and marketing	17,584	12,477
General and administrative	7,813	6,904
Intangible asset amortization	1,275	267
Total operating expenses	43,322	31,596
Loss from operations	(12,200)	(2,067)
Interest expense	(55)	(303)
Other income, net	539	453
Net loss and comprehensive loss	(11,716)	(1,917)
Comprehensive loss	$ (11,716)	$ (1,917)
Net loss per common share, basic and diluted (in usd per share)	$ (0.24)	$ (0.05)
Shares used to compute net loss per common share, basic and diluted (in shares)	49,792,631	41,168,593
Testing
Total Revenue	$ 26,991	$ 25,389
Operating expenses:
Cost of testing revenue	10,568	8,513
Product
Total Revenue	3,409	0
Operating expenses:
Cost of testing revenue	1,559	0
Biopharmaceutical
Total Revenue	722	4,140
Operating expenses:
Cost of testing revenue	$ 116	$ 0